BTIG analyst Ryan Zimmerman maintained a Buy rating.

Source: https://www.benzinga.com/news/23/10/35086481/alphabet-to-rally-over-10-here-are-10-other-analyst-forecasts-for-wednesday

BTIG Research assumed coverage on Affirm in a research report on Tuesday, June 13th.

Source: https://www.dailypolitical.com/2023/06/25/affirm-nasdaqafrm-coverage-initiated-by-analysts-at-compass-point.html

BTIG Research boosted their price objective on shares of Abbott Laboratories from $125.00 to $130.00 and gave the company a “buy” rating in a research report on Monday, April 17th.

Source: https://www.etfdailynews.com/2023/04/22/abbott-laboratories-nyseabt-given-new-122-00-price-target-at-jpmorgan-chase-co/

BTIG Research boosted their target price on Axsome Therapeutics from $62.00 to $98.00 and gave the stock a “buy” rating in a report on Friday, December 23rd.

Source: https://www.americanbankingnews.com/2023/02/22/axsome-therapeutics-inc-nasdaqaxsm-stake-decreased-by-fora-capital-llc.html

BTIG Research boosted their target price on shares of Intuitive Surgical from $326.00 to $373.00 in a report on Monday, July 17th.

Source: https://www.etfdailynews.com/2023/09/03/franklin-resources-inc-acquires-13653-shares-of-intuitive-surgical-inc-nasdaqisrg/

BTIG Research downgraded shares of Fortinet from a “buy” rating to a “neutral” rating in a research report on Friday, January 13th.

Source: https://www.etfdailynews.com/2023/02/10/fortinet-nasdaqftnt-price-target-raised-to-72-00-at-wells-fargo-company/

BTIG Research lowered shares of Taylor Morrison Home from a “buy” rating to a “neutral” rating in a research report on Thursday, October 27th.

Source: https://www.etfdailynews.com/2023/02/13/allianz-asset-management-gmbh-makes-new-investment-in-taylor-morrison-home-co-nysetmhc/

BTIG Research lowered shares of Unity Software from a “buy” rating to a “neutral” rating in a research report on Thursday, December 8th.

Source: https://www.etfdailynews.com/2023/02/05/first-republic-investment-management-inc-has-914000-stock-position-in-unity-software-inc-nyseu/

BTIG Research raised their target price on shares of Starwood Property Trust from $19.00 to $21.00 in a report on Friday, June 30th.

Source: https://www.etfdailynews.com/2023/08/28/credit-suisse-ag-has-8-48-million-holdings-in-starwood-property-trust-inc-nysestwd/

BTIG Research reduced their price objective on shares of Annexon from $15.00 to $7.00 in a report on Thursday, May 25th.

Source: https://www.etfdailynews.com/2023/08/09/cantor-fitzgerald-trims-annexon-nasdaqannx-target-price-to-13-00/

BTIG Research reduced their target price on shares of Protagonist Therapeutics to $41.00 in a report on Wednesday, November 16th.

Source: https://www.etfdailynews.com/2023/03/11/24332-shares-in-protagonist-therapeutics-inc-nasdaqptgx-purchased-by-tudor-investment-corp-et-al/

BTIG Research restated a “buy” rating and set a $70.00 price target on shares of Arcus Biosciences in a research note on Wednesday.

Source: https://www.etfdailynews.com/2023/08/26/federated-hermes-inc-buys-2203-shares-of-arcus-biosciences-inc-nysercus-2/

BTIG Research’s price target would suggest a potential upside of 146.91% from the company’s previous close.

Source: https://www.dailypolitical.com/2023/02/09/cleanspark-nasdaqclsk-price-target-cut-to-8-00-by-analysts-at-btig-research.html

BTIG Research started coverage on eXp World in a research report on Monday, July 17th.

Source: https://www.etfdailynews.com/2023/08/11/exp-world-holdings-inc-nasdaqexpi-insider-james-bramble-sells-38000-shares/

BTIG Research upped their target price on Boston Scientific from $62.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, September 21st.

Source: https://www.dailypolitical.com/2023/11/28/boston-scientific-co-nysebsx-shares-purchased-by-franklin-resources-inc.html

But BTIG technical strategist Jonathan Krinsky said that there are a few names that “appear to be working out of small bases.”

Source: https://seekingalpha.com/article/4657270-wall-street-lunch-reaching-for-the-skies?source=feed_all_articles

Finally, BTIG Research cut their price target on shares of AtriCure from $65.00 to $55.00 and set a “buy” rating for the company in a report on Wednesday, February 22nd.

Source: https://www.etfdailynews.com/2023/05/08/atricure-inc-nasdaqatrc-shares-sold-by-oppenheimer-asset-management-inc/

Finally, BTIG Research lowered shares of Paramount Group from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 19th.

Source: https://www.americanbankingnews.com/2023/02/03/caprock-group-inc-invests-92000-in-paramount-group-inc-nysepgre.html

Finally, BTIG Research lowered their price objective on Evolent Health from $55.00 to $45.00 and set a “buy” rating for the company in a research report on Wednesday, October 12th.

Source: https://www.etfdailynews.com/2023/01/13/allspring-global-investments-holdings-llc-boosts-stock-holdings-in-evolent-health-inc-nyseevh/

Finally, BTIG Research lowered their price objective on shares of Anavex Life Sciences from $35.00 to $28.00 and set a “buy” rating for the company in a report on Thursday, February 9th.

Source: https://www.etfdailynews.com/2023/05/26/citigroup-inc-trims-stock-position-in-anavex-life-sciences-corp-nasdaqavxl/